CDKN2A and sarcoma: Consistent with previous reports, this study revealed that the most common gene alterations in patients with sarcoma were TP53 (36.8%), RB1 (19.9%), CDKN2A (17.6%), CDK4 (16.2%), and MDM2 (13.2%).